

Addison Pierce

Partner



afpierce@cooley.com

+1 312 881 6625

Chicago

Debt Finance
Capital Markets
Private Equity
Life Sciences and Healthcare

Addison advises investors, lenders and life sciences companies on structured financings, with a focus on royalty and revenue transactions. He represents public and private companies, private equity firms, banks and nonbank lenders in a range of financing and corporate matters. His practice spans the full spectrum of debt financing and capital markets transactions, including acquisition financings, secured and unsecured credit facilities, and high-yield and investment-grade bond offerings.

Addison's representative matters include:

Lender-side engagements

- Blue Owl Capital in its:
 - \$140 million royalty-backed debt financing provided to XOMA Corporation
 - \$1.05 billion financing provided to BridgeBio Pharma, consisting of a \$300 million royalty financing and a \$450 million credit facility
 - Up to \$262.5 million in term loans to ITM Isotope Technologies
 - Up to \$250 million in term loans to TG Therapeutics
 - Up to \$500 million in term loans to Madrigal Pharmaceuticals
- HealthCare Royalty in its up to \$250 million in term loans to TG Therapeutics
- Sixth Street in its up to \$910 million strategic investment in Blueprint Medicines, consisting of a \$250 million royalty financing and an up to \$660 million credit facility

Borrower-side engagements

- Geron Corporation in its up to \$375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors
- Nuvation Bio in its up to \$250 million in term loan and royalty financings with Sagard Healthcare Partners
- Dermavant Sciences in its \$160 million revenue financing and \$40 million term loan
- Cara Therapeutics in its \$40 million royalty interest purchase and sale agreement with HealthCare Royalty Partners
- Reata Pharmaceuticals in its \$275 million debt financing from funds managed by Pharmakon Advisors
- Clearside Biomedical in its \$65 million royalty interest purchase and sale agreement with HealthCare

Royalty Partners

- Mirum Pharmaceuticals in its \$210 million financing arrangement with Oberland Capital Management
- Paratek Pharmaceuticals in its \$60 million nonrecourse loan from R-Bridge Healthcare Investment Advisory, an affiliate of CBC Group
- Uber Technologies in its:
 - \$4 billion investment grade bond offering
 - \$1 billion aggregate principal amount of 7.5% senior notes due 2025
- BioMarin Pharmaceutical in its \$600 million unsecured revolving credit facility
- Tempus AI in its \$600 million acquisition of Ambry Genetics
- Sprout Social in its \$140 million acquisition of Tagger Media
- NETSTREIT in its more than \$1.5 billion in unsecured credit facilities

Education

Washington College of Law American University JD, magna cum laude, 2015

Oakland University BA, International Relations, cum laude, 2011

Admissions & Credentials

District of Columbia

New York

Illinois